1. The company has been the domestic nucleic acid diagnostic reagent leader, in the reagent R & D and production bigger and stronger at the same time, relying on the advanced technology in the field of test reagents and strong strength, established by the production, R & D, sales, service and independent laboratories composed of interdependent, each other to promote the development of the *** with the complete profitability of the system, for the long-term development of the enterprise to lay the foundation.
2. The company and its two holding subsidiaries, Guangzhou Daan Clinical Laboratory Center Co. The company and the above holding subsidiaries from the high-tech enterprise recognized within three years (2008 to 2010), the income tax rate of 15% of the rate.
3. The company's main financial indicators for the first three quarters of 2009: earnings per share of 0.1400 (yuan), net assets per share of 1.4800 (yuan), return on net assets of 9.5500%, operating income of 224755611.2600 (yuan), year-on-year increase or decrease of 25.8464%; attributable to shareholders of the listed company's net profit 34060624.38 (yuan), year on year increase or decrease. ), year-on-year increase or decrease of 42.9145%.
4. The company's 2008 annual equity distribution program is: 2 bonus shares for every 10 shares, RMB 0.26 cash (tax included). Equity registration date: June 9, 2009; ex-rights and ex-dividend date: June 10, 2009. 5. July 3, 2009, the company's de facto controller, CU Holdings through the centralized bidding trading system to sell the company's circulation of 2 million shares, accounting for the company's total share capital of 0.83%.
6. On September 27, 2009, the company obtained the medical device registration certificate for Influenza A (H1N1) Virus (2009) RNA Detection Kit (PCR-Fluorescent Probe Method) issued by the State Food and Drug Administration.
7. The company passed the first phase of equity incentive draft, granting incentive recipients 2.16 million stock options, corresponding to the underlying shares of 2.16 million shares, accounting for 0.8971% of the total share capital, the exercise price of 17.11 yuan.